Interestingly, a targeted delivery strategy, which modified cell-penetrating TAT peptide by using CSF-1R inhibitor, successfully activate immune response through blocking the CSF-1/CSF-1R pathway and reducing M2 macrophages and thus promoting anti-tumor effector CD8+T-lymphocyte infiltration in “cold” colon cancer 64. The gene discussed is CSF1; the disease is colonic neoplasm.